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Objective: New diagnostic criteria for mild cognitive impairment (MCI) due to Alzheimer’s
disease (AD) have been developed using biomarkers aiming to establish whether the
clinical syndrome is likely due to underlying AD. We investigated the utility of magnetic
resonance imaging (MRI) and cerebrospinal ﬂuid (CSF) biomarkers in predicting progression
from amnesic MCI to dementia, testing the hypotheses that (1) markers of amyloid
and neurodegeneration provide distinct and complementary prognostic information over
different time intervals, and that (2) evidence of neurodegeneration in amyloid-negative
MCI individuals would be useful prognostically.
Methods: Data were obtained from the ADNI-1 (Alzheimer’s Disease Neuroimaging
Initiative Phase 1) database on all individuals with a baseline diagnosis ofMCI, baselineMRI
and CSF data, and at least one follow-up visit. MRI data were processed using a published
set of a priori regions of interest to derive a measure known as the “AD signature,” as well
as hippocampal volume. The CSF biomarkers amyloid-β, total tau, and phospho tau were
also examined. We performed logistic regression analyses to identify the best baseline
biomarker predictors of progression to dementia over 1 or 3 years, and Cox regression
models to test the utility of these markers for predicting time-to-dementia.
Results: For prediction of dementia in MCI, the AD signature cortical thickness biomarker
performed better than hippocampal volume. Although CSF tau measures were better than
CSF amyloid-β at predicting dementia within 1 year, the AD signature was better than all
CSF measures at prediction over this relatively short-term interval. CSF amyloid-β was
superior to tau and AD signature at predicting dementia over 3 years. When CSF amyloid-
β was dichotomized using previously published cutoff values and treated as a categorical
variable, a multivariate stepwise Cox regressionmodel indicated that both theAD signature
MRI marker and the categorical CSF amyloid-β marker were useful in predicting time-to-
event diagnosis of AD dementia.
Conclusion: In amnesic MCI, short-term (1 year) prognosis of progression to dementia
relates strongly to baseline markers of neurodegeneration, with the AD signature MRI
biomarker of cortical thickness performing the best among MRI and CSF markers studied
here. Longer-term (3 year) prognosis in these individuals was better predicted by a marker
indicative of brain amyloid. Prediction of time-to-event in a survival model was predicted by
the combination of these biomarkers. These results provide further support for emerging
models of the temporal relationship of pathophysiologic events in AD and demonstrate the
utility of these biomarkers at the prodromal stage of the illness.
Keywords: Alzheimer’s disease, MRI, biomarkers, mild cognitive impairment, CSF biomarkers
INTRODUCTION
When insidious in onset and gradually progressive, mild cognitive
impairment (MCI) is a clinical syndrome commonly arising as a
result of neurodegenerative pathology (Petersen et al., 2006). In
living persons, evidence of neurodegenerative pathology is pro-
vided by a growing array of imaging and ﬂuid biomarkers. If the
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goal is to determine whether MCI appears highly likely to be due
to underlying Alzheimer pathology, the recently published MCI
diagnostic criteria require evidence of (1) cerebral amyloidosis
[amyloid positron emission tomography (PET) or cerebrospinal
ﬂuid (CSF) amyloid-β] and (2) neurodegeneration [magnetic
resonance imaging (MRI)-derived atrophy, ﬂuorodeoxyglucose
(FDG)-PET-derived hypometabolism, or CSF tau; Albert et al.,
2011]. A number of studies have now shown that, within a group
of persons with MCI, the presence and prominence of these
biomarkers are predictive of the likelihood of Alzheimer’s dis-
ease (AD) dementia within a few years (Jack et al., 1999; Hansson
et al., 2006; Wang et al., 2006; Vemuri et al., 2009b; Visser et al.,
2009; Blennow et al., 2010; De Meyer et al., 2010; Jack et al., 2010;
Landau et al., 2010; Buchhave et al., 2012). Despite the importance
of observations from these studies, a number of questions remain,
particularly when considering how to use biomarkers in the design
of clinical trials of putative interventions. Further, as more clin-
icians are beginning to incorporate these measures into clinical
practice, a deeper understanding of the relative implications of
these biomarkers is critical.
In persons with MCI, what are the best MRI-derived biomark-
ers of neurodegeneration with regard to prediction of progression
to dementia? One very commonly used measure is hippocampal
volume, which has consistently been shown to predict dementia
in MCI (Frisoni et al., 2010). We have developed an AD signature
cortical thicknessmarker (Dickerson et al., 2009), and hypothesize
that this marker will outperform commonly used MRI-derived
biomarkers as an indicator of AD-related neurodegeneration in
MCI that is predictive of AD dementia.
Another major question relates to the temporal utility of
biomarkers. What are the best markers for short-term vs. longer-
term prediction of dementia? Although current clinico-pathologic
constructs of AD require evidence of cerebral amyloidosis, data
are conﬂicting as to whether markers of amyloid or neurodegen-
eration best predict dementia and to our knowledge none have
speciﬁcally tested hypotheses about the comparative utility of
amyloid vs. neurodegenerative markers at different time intervals.
We tested two hypothesis here: (1) rapid progression (i.e., over
1 year) from MCI to AD dementia is better predicted by mark-
ers of neurodegeneration rather than the presence of amyloid; (2)
longer-term progression from MCI to dementia (i.e., 3 years) is
best predicted by the presence of abnormal levels of brain amyloid.
This prediction follows from the notion that cerebral amyloidosis
may be a relatively earlier development in AD pathophysiology
compared to evidence of neurodegeneration measured using in
vivomethods (Jack et al., 2013). Further, neurodegenerativemark-
ers appear to be more sensitive to disease state than measures
of cerebral amyloid (Jack et al., 2009; Vemuri et al., 2009a). As
such, amyloid measures may differentiate individuals who will
eventually progress to AD over longer-term follow-up while neu-
rodegenerative markers may indicate an elevated risk for more
proximate cognitive decline and dementia.
Finally, the focus of a number of studies of biomarker predic-
tion of AD dementia in amnestic MCI has been on the 50–75%
of subjects with evidence of cerebral amyloidosis. What about the
other individuals, especially those whomay show evidence sugges-
tive of neurodegeneration (Knopman et al., 2012; Petersen et al.,
2013)? Are MRI-derived markers useful in predicting dementia
in individuals with MCI who do not have evidence of cerebral
amyloidosis?
Here we undertook a set of analyses of the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) dataset to investigate these
questions, focusing on the utility of MRI and CSF biomarkers for
prognosis in MCI.
MATERIALS AND METHODS
PARTICIPANTS
Data used in the preparation of this article were obtained from the
ADNI database1. The ADNI was launched in 2003 by the National
Institute on Aging (NIA), the National Institute of Biomedical
Imaging and Bioengineering (NIBIB), the Food and Drug Admin-
istration (FDA), private pharmaceutical companies, and non-
proﬁt organizations, as a $60 million, 5-year public–private part-
nership. The primary goal of ADNI has been to test whether serial
MRI,PET,other biologicalmarkers, and clinical and neuropsycho-
logical assessment can be combined to measure the progression of
MCI and earlyAD.Determinationof sensitive and speciﬁcmarkers
of very earlyADprogression is intended to aid researchers and clin-
icians to develop new treatments and monitor their effectiveness,
as well as lessen the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W.
Weiner,MD,VAMedical Center andUniversity of California – San
Francisco. ADNI is the result of efforts of many co-investigators
from a broad range of academic institutions and private corpora-
tions, and subjects have been recruited from over 50 sites across
the U.S. and Canada. The initial goal of ADNI was to recruit 800
subjects but ADNI has been followed by ADNI-GO and ADNI-
2. To date these three protocols have recruited over 1500 adults,
ages 55–90, to participate in the research, consisting of cogni-
tively normal older individuals, people with early or late MCI, and
people with early AD. The follow-up duration of each group is
speciﬁed in the protocols for ADNI-1, ADNI-2, and ADNI-GO.
Subjects originally recruited for ADNI-1 and ADNI-GO had the
option to be followed in ADNI-2. For up-to-date information, see
www.adni-info.org.
For the current analysis, we selected individuals with a baseline
diagnosis of MCI who had baseline MRI and CSF data available,
and at least 1 year of clinical follow-up (n = 154). Detailed diag-
nostic, inclusion, and exclusion criteria are described on theADNI
website2.
STANDARD PROTOCOL APPROVALS, REGISTRATIONS, AND PATIENT
CONSENTS
Each participant gave written informed consent in accordance
with institutional Human Subjects Research Committee guide-
lines.
MRI IMAGING AND ANALYSIS
Magnetic resonance imaging scans were collected on a 1.5T
scanner using a standardized MPRAGE protocol: sagittal plane,
TR/TE/TI, 2400/3/1000 ms, ﬂip angle 8◦, 24 cm FOV, 192 × 192
1www.adni.loni.ucla.edu
2http://www.adni-info.org/
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in-plane matrix, 1.2 mm slice thickness (Jack et al., 2008). Fully
pre-processed scans were downloaded for analysis.
T1 image volumes were examined quantitatively by a cortical
surface-based reconstruction and analysis of cortical thickness,
using a hypothesis-driven approach as described in multiple pre-
vious publications (Bakkour et al., 2009; Dickerson et al., 2009,
2011;Wolk et al., 2010). Brieﬂy, we utilized nine regions of interest
(ROIs, see Figure 1) previously determined to be associated with
AD, the“cortical signature”of AD (Bakkour et al., 2009; Dickerson
et al., 2009).
For the purposes of this study, we employed a primary diag-
nostic biomarker, the single summary “AD signature measure,”
the average thickness of all nine ROIs. With the goal of adjust-
ing this measure for normal age-related inﬂuences on these brain
regions, we also measured a set of “Aging signature” ROIs, as pre-
viously published (Bakkour et al., 2013). We calculated an “AD
signature index” measure by ﬁrst performing a linear regression
in the amyloid-negative control group with the Aging signature as
the independent variable and the AD signature as the dependent
variable. We then used this equation to calculate the “AD signa-
ture index values for each MCI patient.” Thus, an individual with
a lower AD signature index value has cortical thickness within
the AD signature ROIs that is disproportionately smaller than
the thickness of the Aging signature ROIs, likely reﬂecting more
speciﬁc AD-related neurodegeneration. Alternatively, an individ-
ual with a higher AD signature index value has cortical thickness
within the AD signature ROIs that is of similar relative magnitude
to Aging signature ROIs, possibly reﬂecting more diffuse effects.
In addition, for comparison purposes, we analyzed hippocam-
pal volume using themeasure provided by the automated segmen-
tation procedure from FreeSurfer, divided by total intracranial
volume. Our standard procedure is to visually inspect selected
coronal slices of each automated segmentation and identify scans
with errors in processing of the structure of interest. We also
inspect the distribution of the quantitative volumetric data and
review scans at either tail of the distribution and outliers in
greater detail. In the present analysis, no scans were identiﬁed
with important errors of hippocampal segmentation.
BASELINE CEREBROSPINAL FLUID MEASURES
We also examined baseline CSF levels of amyloid-β, total tau (t-
tau), and phosphorylated tau (p-tau). For the primary analyses, we
used the raw values as continuous measures; however, t-tau and
p-tau were log-transformed to better approximate normality in
distribution. For analyses in which we classiﬁed subjects as having
CSF amyloid-β values consistentwith those of autopsy-provenAD,
we used a cutoff value of levels less than 192 (Shaw et al., 2009).
Individuals with levels≥192were considered to be unlikely to have
cerebral amyloidosis.
LONGITUDINAL OUTCOMES
Here we used outcomes at 1 or 3 years. The primary outcomemea-
sures used in the present analysis were conversion to a diagnosis
of AD dementia at 1 or at 3 years.
STATISTICAL ANALYSIS
Tests of group differences were performed using Chi-square anal-
ysis (for frequencies) or Analysis of Variance (for continuous
measures) with post hoc pairwise comparisons where relevant;
a = 0.05. Since effect sizes were expected to be subtle and strong
a priori hypotheses were being tested, no multiple comparisons
correction procedures were performed. In addition, the impact
of biomarkers on clinical outcome was analyzed using separate
logistic regression models for each of the two intervals of follow-
up, constructed using the dichotomous conversion to dementia
outcomemeasure as the dependent variable. Cox regression mod-
els were constructed to investigate the relationship of baseline
biomarkers to the likelihood of progression to AD dementia using
a more ﬁne-grained time-to-event outcome rather than the two
follow-up intervals employed in the other analyses. A multivariate
FIGURE 1 | (A) The cortical signature of AD is composed of a priori
regions of interest in which consistent atrophy has been previously
observed in multiple samples of patients with mild AD dementia. (B) The
cortical signature of normal aging is composed of a priori regions of
interest in which consistent atrophy has been previously described in
healthy cognitively intact older adults compared with younger adults. We
calculated the “AD signature index” measure by performing a linear
regression with the Aging signature (excluding regions overlapping with AD
signature regions; see Figures 1 and 2 of Bakkour et al., 2013) as the
independent variable and the AD signature as the dependent variable. The
residuals of this regression analysis were then saved as the “AD signature
index.” Key: A: medial temporal, B: inferior temporal, C: temporal pole, D:
Angular, E: superior frontal, F: superior parietal, G: supramarginal, H:
precuneus, I: middle frontal, J: calcarine, K: caudal insula, L: cuneus, M:
caudal fusiform, N: dorsomedial frontal, O: lateral occipital, P: precentral,
Q: inferior frontal.
Frontiers in Aging Neuroscience www.frontiersin.org October 2013 | Volume 5 | Article 55 | 3
“fnagi-05-00055” — 2013/10/9 — 21:58 — page 4 — #4
Dickerson andWolk Biomarker prediction of progression in MCI
Cox regression model was then constructed including indepen-
dent variables that reached a trend-level effect (p < 0.1) in the
univariate analyses (p-value-to-enter <0.05). Covariates of age,
education, and gender were generally not signiﬁcant in the mod-
els and had minimal impact on the ﬁndings. Statistical analyses
were performed using IBM SPSS 21.0.
RESULTS
Of the 156MCI participants with baselineMRI and CSF data who
were followed for 1 year, 31 (20%) were diagnosed with probable
AD dementia. Of the 111 who had 3-year outcome data, 48 (43%)
were diagnosed with probable AD dementia. In the subset of MCI
participants with baseline CSF evidence of cerebral amyloidosis,
26 of 116 (22%) were diagnosed with probable AD dementia at
1 year and 45 of 83 (54%) at 3 years. In contrast, in the subgroup
of MCI participants with normal baseline CSF amyloid-β levels,
only 5 of 40 (13%) converted to AD dementia at 1 year and 3 of
27 (11%) at 3 years. See Table 1 for additional details.
We ﬁrst sought to determine which of the baseline biomark-
ers would be useful in prediction of the likelihood of a diagnosis
of probable AD dementia in the entire sample of MCI subjects.
For the 1-year outcome interval, baseline cortical thickness mea-
sured with the AD signature MRI biomarker index was strongly
associated with the likelihood of probable AD: a logistic regres-
sion model predicting a 1-year AD outcome indicated a nearly
threefold increase in the likelihood of AD dementia for each 1
SD thinner cortex [odds ratio (OR) = 2.7, 95% C.I.: [1.7–4.5],
p < 0.0001). In addition, baseline CSF p-tau levels were predic-
tive of AD dementia, with each 1 SD increase in CSF p-tau levels
being associated with a 1.7-fold increase in the likelihood of AD
dementia (OR = 1.7, 95% C.I.: [1.09–2.7], p = 0.02). None of
the other biomarkers demonstrated effects or trend-level effects.
In the stepwise multivariate logistic regression model, the AD sig-
nature MRI marker entered but CSF p-tau did not, indicating that
CSF p-tau did not explain additional variance in outcome beyond
that explained by the AD signature MRI marker.
In contrast, 3-year conversion was best predicted by baseline
CSF amyloid-β levels, with each 1 SDof reduction indicating a 1.9-
fold increase in 3-year likelihood of AD dementia (OR = 1.9, 95%
C.I.: [1.2–3.0], p= 0.003). A slightlyweaker effect was observed for
theAD signature index (OR= 1.7, 95%C.I.: [1.12–2.6], p = 0.01).
Signiﬁcant effects were also observed for CSF p-tau (OR = 1.8,
95% C.I.: [1.14–2.7], p = 0.01) and CSF t-tau (OR = 1.6, 95%
C.I.: [1.06–2.5], p = 0.03) while hippocampal volume displayed a
strong trend (OR = 1.5, 95% C.I.: [1.00–2.29], p = 0.05). In the
stepwise multivariate model, CSF amyloid-β entered but the other
two did not.
Figure 2 depicts the values for the AD signature cortical thick-
ness MRI marker and CSF amyloid-β for each of the three MCI
subgroups based on outcome (stable over 3 years, 3-year con-
verters who did not convert by year 1, and 1-year converters).
The mean values for CSF amyloid-β are lower in both groups
of converters than in stable MCI (1-year: p < 0.05; 3-year:
p < 0.01), but there is no difference based on year of conver-
sion (p > 0.3). Alternatively, values for AD signature cortical
thickness are lower for both groups of converters than the sta-
ble group (1-year: p < 0.001; 3-year: p = 0.05), but also for the
1-year converters compared to the 3-year converters (p< 0.05; all
values shown are Z scores derived from the normative values of
controls).
We next investigated the utility of biomarkers for prediction of
a diagnosis of AD dementia in subgroups of MCI subjects divided
on the basis of baseline CSF amyloid-β levels. In the subgroup of
MCI subjects with abnormally low baseline CSF amyloid-β lev-
els (consistent with cerebral amyloidosis), 1-year conversion to
AD dementia was predicted by the AD signature MRI biomarker
(OR = 2.2, 95% C.I.: [1.3–3.8], p = 0.005). None of the other
biomarkers were predictive in these univariate models. For 3-
year prediction, a signiﬁcant effect for the AD signature MRI
biomarker (OR= 1.7, 95%C.I.: [1.1–2.7],p= 0.03) and a trend for
hippocampal volume (OR = 1.5, 95% C.I.: [0.95–2.5], p = 0.08)
were observed.
Table 1 | Demographic and baseline biomarker characteristics of sample.
Subject group 1-year outcome (N = 156) 3-year outcome (N = 111)
N (%) or M (SD) MCI (N = 125) AD (N = 31) MCI (N = 63) AD (N = 48)
Age (years) 74.9 (7.6) 72.3 (6.90) 74.7 (7.3) 74.3 (7.7)
Gender 84 M: 41 F 17 M: 14 F 47 M: 16 F 30 M: 18 F
Education (years) 15.8 (3.0) 15.1 (3.2) 15.6 (3.0) 15.6 (3.4)
MMSE 27.5 (1.7) 26.7 (1.9) 27.3 (1.8) 26.7 (1.9)
CDR-SB 1.9 (0.8) 2.4 (0.9)* 1.7 (0.6) 2.2 (1.0)*
CSF amyloid-β Z score −0.73 (1.00) −0.99 (0.70) −0.56 (1.12) −1.15 (0.65)**
CSFTotal tau Z score 0.69 (1.07) 1.17 (1.13) 0.74 (1.22) 1.26 (1.13)*
CSF P-tau Z score 0.69 (1.06) 1.20 (0.99)* 0.62 (1.04) 1.12 (0.93)*
AD signature Z score −0.82 (1.13) −1.82 (1.27)** −0.63 (1.12) −1.26 (1.19)*
Hippo vol Z −0.94 (1.14) −1.24 (1.06) −0.75 (1.05) −1.15 (1.04)†
*p < 0.05, **p < 0.005 groups are different from each other.
†p = 0.05, groups demonstrate trend-level difference from each other.
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FIGURE 2 |Values for the AD signature cortical thickness and CSF
amyloid-β for each of the three MCI subgroups based on outcome
(stable over 3 years, 3-year converters, and 1-year converters).The
mean values for CSF amyloid-β are lower in both groups of converters than
in stable MCI (left), while the values for AD signature index of cortical
thickness are lower in the 1-year converters than in the other two groups
(right; all values shown are Z scores derived from the normative values of
controls and bars represent statistically signiﬁcant comparisons).
In the subgroup of MCI subjects with normal CSF amyloid-β
levels, indicating the likely absence of cerebral amyloidosis, 1-year
conversion toADdementia was best predicted by theAD signature
MRI biomarker (OR = 6.4, 95% C.I.: [1.5–27.5], p = 0.01), with
hippocampal volume showing utility as well (OR = 3.5, 95% C.I.:
[1.2–10.7], p = 0.03) but not entering the multivariate model.
None of the CSF markers demonstrated predictive value. For 3-
year prediction, none of the markers were useful although power
was extremely low due to the small number of individuals who
were diagnosed with AD dementia.
Finally, we performed a survival analysis to investigate the util-
ity of these biomarkers for predicting the time to a diagnosis of AD
dementia. Univariate Cox proportional hazards regression mod-
els indicated that each of the biomarkers was a predictor of time
to diagnosis of AD dementia over the 3-year follow-up period
(Table 2). In multivariate analysis, a stepwise forward conditional
model demonstrated that the AD signature MRI biomarker was
the best and only predictor when each independent variable was
entered as a continuous variable. However, when CSF amyloid-β
was dichotomized using previously published cutoff values (Shaw
et al., 2009) and treated as a categorical variable, the multivariate
stepwise Cox regression model indicated that both the AD signa-
ture MRI marker and the categorical CSF amyloid-βmarker were
useful in predicting time-to-event diagnosis of AD dementia. Of
all the models, this was the model with the overall strongest sta-
tistical results (X2 = 19.4, p < 0.001). This result is illustrated in
Figure 3 inwhich theADsignaturewas also dichotomized tomaxi-
mize sensitivity and speciﬁcity between amyloid-negative controls
and amyloid-positive mild AD patients from the ADNI cohort.
Finally, to begin to assess the speciﬁcity of the reﬁned AD sig-
nature index measure we analyzed the relationships between CSF
biomarkers and the rawADsignaturemeasure (inmillimeters) and
the adjusted AD signature index measure (adjusted for thickness
of the Aging signature regions as described in Section “Materials
Table 2 | Results of Cox regression analyses of baseline CSF and MRI
biomarker measures predicting probable AD diagnosis.
X 2 HR 95% CI
AD signature 13.7 (p < 0.001)** 1.61 1.25–2.08
AD signature dichotomous 12.9 (p < 0.001)** 2.28 1.44–3.63
CSF amyloid-β
dichotomous
12.2 (p < 0.001)** 3.66 1.68–7.99
CSF amyloid-β 7.4 (p < 0.01)* 1.42 1.10–1.83
CSF p-tau 9.2 (p < 0.01)* 1.47 1.15–1.90
CSF t-tau 5.5 (p < 0.05)* 1.33 1.05–1.70
Hippocampal volume 4.8 (p < 0.05)* 1.31 1.03–1.67
Combination of CSF
dichotomous amyloid-β
and AD signature
19.4 (p < 0.0001)** Aβ 3.0
ADsig 1.4
1.38–6.7
1.07–1.77
*p < 0.05, **p < 0.005.
and Methods.” The adjusted AD signature index exhibited sub-
stantially stronger correlations (Table 3) with all CSF biomarkers
relative to the raw AD signature, suggesting that this adjustment
for “brain age” improves the speciﬁcity of this MRI biomarker for
AD-related neurodegeneration.
DISCUSSION
When individuals are diagnosed with MCI, the two most pressing
clinical questions relate to etiology and prognosis. We now have
a growing armamentarium of biomarkers for AD and other neu-
rodegenerative diseases, and reasonably mature diagnostic criteria
for “MCI of the Alzheimer type” (Albert et al., 2011) which hinge
on a typical clinical syndrome and the presence of one or more
imaging or ﬂuid biomarkers. In this analysis, we used ADNI data
to test two major hypotheses in patients with MCI: (1) markers
of amyloid and neurodegeneration provide distinct and comple-
mentary prognostic information over different time intervals, and
that (2) evidence of neurodegeneration in amyloid-negative MCI
individuals is useful prognostically. We found compelling support
for both hypotheses.
For prediction of AD dementia in MCI, the AD signature
cortical thickness biomarker performed better than hippocampal
volume. Although CSF tau measures, also putative neurodegen-
erative biomarkers, were better than CSF amyloid-β at predicting
dementia within 1 year, the AD signature was better than all CSF
measures at prediction over this relatively short-term interval. CSF
amyloid-β was superior to tau and AD signature at predicting
dementia over 3 years. In an analysis examining the combined use
of CSF andMRImeasures,whenCSF amyloid-βwas dichotomized
using previously published cutoff values and treated as a categor-
ical variable, a Cox regression model indicated that both the AD
signature MRI marker and the categorical CSF amyloid-β marker
were useful in predicting time-to-event diagnosis of AD demen-
tia. These results provide further support for emerging models
of the pathophysiology of AD and demonstrate the utility of the
combined use of these biomarkers at the prodromal stage of the
illness (Jack et al., 2010; Landau et al., 2010; Vemuri et al., 2010).
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FIGURE 3 | Survival curves in MCI participants who were “amyloid-negative” at baseline (left) vs. those who were “amyloid positive” (right) as a
function of baseline AD signature index using dichotomous cutoff.
Table 3 | Relationships of CSF biomarkers to MRI biomarkers.
Age CSF t-tau CSF p-tau CSF amyloid-β
Aging signature r = −0.38 (p < 0.001) r = −0.05 NS r = −0.04 NS r = −0.06 NS
AD signature r = −0.30 (p < 0.001) r = −0.26 (p < 0.01) r = −0.21 (p < 0.01) r = −0.09 NS
Adjusted AD signature r = 0.05 NS r = −0.37 (p < 0.001) r = −0.35 (p < 0.001) r = 0.22 (p < 0.01)
Hippocampal volume r = −0.19 (p < 0.05) r = −0.04 NS r = −0.03 NS r = 0.05 NS
Amajor novel contribution of the present study is the investiga-
tion of the prognostic utility of different biomarkers over intervals
of varying times after the markers were obtained at baseline. To
our knowledge, no prior study has explicitly examined separate
follow-up intervals in MCI and measured the differential util-
ity of amyloid vs. structural MRI markers. As we plan clinical
trials of pharmacologic and non-pharmacologic interventions in
MCI, it is critical not only to consider methods to homogenize
the patient population for inclusion (e.g., requiring MCI patients
to have cerebral amyloidosis for inclusion); it may also be valu-
able in some trial designs to use a marker of neurodegeneration to
identify patients in whom progression to dementia is likely within
a relatively short time interval, such as 1 year. Such a stratiﬁed
design for inclusion might be valuable in that most such partici-
pants would be likely to decline substantially during a reasonable
follow-up interval, thereby maximizing power to detect a bene-
ﬁcial effect of the intervention. Of course, it is also possible that
in these more “aggressive” cases of prodromal AD a drug might
be less efﬁcacious than in more indolent forms of the disease, but
that remains an open question.
These considerations are also becoming of greater relevance in
clinical practice, particularly in light of recent FDA approval of the
amyloid PET ligand ﬂorbetapir. Further, with the development of
the above-described guidelines for incorporation of biomarkers
into the assessment of MCI patients, it is likely that clinicians will
be bringing these measures into their clinical practice for prog-
nostication of MCI. The current work emphasizes that these tests
may provide somewhat different information, which may have
important implications for their value depending on the question
that is being addressed. For example, MRI may be more valuable
when interested in determining the likelihood of decline in the
near future, which could inﬂuence life decisions that need to be
made within that timeframe whereas the presence of amyloid may
more deﬁnitively reﬂect the likelihood of progression, but have
less value in predicting the timing.
It seems intuitive, based on currentmodels of biomarkers of AD
pathophysiology (Jack et al., 2013), that the presence of cerebral
amyloidosis would be valuable for longer-term prognosis while an
MRI-derived marker of neurodegeneration would demonstrate
utility in shorter-term prognosis. As the individuals with MCI in
this study were followed longitudinally, those with baseline cere-
bral amyloid progressed to dementia at a rate of about 15–20%
per year, while only about 10–15% of those without baseline brain
amyloid progressed to dementia after 3 years,most doing sowithin
the ﬁrst year of follow-up. Those who progressed to AD demen-
tia at 3 years had baseline CSF amyloid-β levels that are similarly
reduced to those who progressed at 1 year. This is consistent with
models that suggest that amyloid deposition is an early feature of
the disease that largely plateaus by the symptomatic stage of disease
resulting in relatively poor resolution of disease state (i.e., proxim-
ity to dementia) at that stage (Villemagne et al., 2013). In contrast,
the baseline MRI-derived AD signature measure of cortical thick-
nesswas substantially lower in individualswhoprogressed at 1 year
than in those who progressed at 3 years (Figure 2). This indicates
that onceAD-related neurodegenerative cortical atrophy is promi-
nent enough in MCI patients, further cognitive decline and loss
of functional independence is imminent. Such a ﬁnding demon-
strates the greater degree by which markers of neurodegeneration,
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particularly structural MRI measures, track disease state during
symptomatic stages of disease.
The differences described here in temporal prediction and,
ultimately, the complementary nature of biomarkers of cerebral
amyloidosis with neurodegeneration are quite consistent with a
number of recent studies in the literature exploring this issue. For
example, Buchhave et al. (2012) recently described that while the
presence of low CSF amyloid-β predicted conversion to AD in
MCI patients, CSF p-tau status was associated with the timing
of this conversion (abnormal: conversion in 0–5 years; normal:
conversion in 5–10 years). Another group, also using the ADNI
dataset, compared dichotomous measures of hippocampal atro-
phy, memory testing, and CSF total tau, p-tau, and amyloid-β
in prediction of conversion. They found that median survival
was generally shorter for neurodegenerative biomarkers while CSF
amyloid-β had the longestmedian time before conversion (Heister
et al., 2011). Further, using a FDG-PET “signature” of AD, simi-
lar to the structural one applied here, Landau et al. (2010) found
that this measure was also superior to CSF amyloid-β for predic-
tion of conversion in MCI patients with mean follow-up under
2 years. This group also described a tighter link between cogni-
tive decline and cerebral amyloidosis, based on amyloid imaging,
in asymptomatic individuals, but stronger association of decline
with FDG-PET status in MCI (Landau et al., 2012). Thus, the cur-
rent ﬁndings serve as additional support for the leading model
of the proposed biomarker cascade (Jack et al., 2013), which has
also found additional veriﬁcation in longitudinal study of asymp-
tomatic dominantly inherited AD mutation carriers (Bateman
et al., 2012).
A variety of MRI measures have been proposed as potential
biomarkers of neurodegeneration in early AD, both with regard
to the identiﬁcation of presumed atrophy consistent with AD
and with regard to monitoring changes over time that indicate
progression of neurodegeneration. Hippocampal volume is the
most widely employed and discussed measure of this type, and
while clearly informative, it is increasingly appearing to be less
sensitive and speciﬁc than other measures such as regional corti-
cal thickness. We have previously shown using receiver operating
characteristic analyses that theAD signaturemeasure is superior to
hippocampal volume in discriminating individuals with prodro-
mal AD who progress to dementia within 3 years from those who
donot (Bakkour et al., 2009). Hereweused logistic andCox regres-
sion models to demonstrate the superiority of the AD signature
over hippocampal volume in predicting progression to dementia
in both amyloid-positive and amyloid-negative individuals with
MCI. Nonetheless, it is worth noting that while not as strongly
predictive of conversion as the AD signature, hippocampal vol-
ume still had predictive value in most of these analyses consistent
with prior work using this measure (for review, see Frisoni et al.,
2010). Further, much of the literature has applied cutoff values or
categorical groupings of hippocampal volumes in similar analyses
to those presented here, which may provide additional predictive
power (Jack et al., 1999, 2010; Landau et al., 2010; Heister et al.,
2011). Future work should explore optimized cutoffs for the AD
signature and other structural measures, allowing for comparison
of these measures in both continuous and dichotomous
forms.
It is also important to note that we compared CSF molecular
biomarkers on an individual basis, as opposed to the combina-
tion of these markers. However, it appears that a combination of
these measures may further enhance prediction (Shaw et al., 2009;
De Meyer et al., 2010). In particular, ratios of t-tau or p-tau to
amyloid-β may improve prediction by incorporating both neu-
rodegenerative and amyloid-based measures, akin to our ﬁnding
that the combination of the AD signature and CSF amyloid-
β produced the strongest model in the Cox regression analysis.
Nonetheless, the current analysis was developed to speciﬁcally
compare across these classes of biomarkers and, as such, we chose
to keep the CSF measures uncoupled.
In thepresent study,we employed anovel approach to the calcu-
lation of our AD signature measure. In the past, we have generally
not adjusted for age-related cortical atrophy, but in some analyses
have simply corrected statistically for a participant’s chronologi-
cal age. We recently reported on the cortical signature of normal
aging (the “Aging signature”), describing a set of association and
sensorimotor regions that undergo the most prominent loss of
thickness in cognitively normal elderly adults compared to young
adults (Bakkour et al., 2013). In the analyses here, we used the
Aging signature set of regions to adjust for the “cortical age” of the
individuals, creating an AD signature index, which represents the
residual variance of the AD signature after accounting for varia-
tions in the Aging signature regional measurements. This corrects
for the fact that some individualsmayhave thinner cortex in at least
some of the regions vulnerable to AD simply as a result of more
widespread cortical atrophy associated with normal aging, while
those with thinner cortex in AD-vulnerable regions who have pre-
served thickness inAging-vulnerable regions aremuchmore likely
to be exhibiting atrophy associated speciﬁcally withAD pathology.
To our knowledge, this type of an adjustment of MRI biomarkers
has not been performed previously. We are continuing to explore
the strengths and weaknesses of this approach.
Finally, our analysis indicated that the MRI-derived AD signa-
ture biomarker was useful for predicting progression to dementia
within 1 year in MCI participants with baseline CSF amyloid-β
levels not low enough to meet typical cutoffs indicating cerebral
amyloidosis. Even though the percentage of individuals who pro-
gressed to dementia in this subgroup was low (13%), the MRI
marker was still useful for prediction in this short time interval.
To interpret this ﬁnding, we have considered several possibilities.
First, it is possible that these individuals have a non-Alzheimer
pathology that is associated with atrophy in some of the same
structures affected by AD. Although this consideration certainly
seems reasonable when the structural MRI measure is of the
hippocampus, since pathologies such as hippocampal sclerosis
could be playing a role, it seems harder to reconcile with an MRI
biomarker measuring a spatially distributed pattern of atrophy.
We are currently examining the use of the AD signature marker in
differential diagnosis of other neurodegenerative diseases, includ-
ing frontotemporal dementias and Lewy body dementia; ﬁndings
from this work will provide important data on the speciﬁcity of
this marker in other neurodegenerative diseases. It is also possible
that these individuals actually have underlying AD pathology but
are “below the threshold” of amyloid pathology to meet current
CSF cutoffs. This group could also be akin to previously reported
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cognitively normal and MCI individuals with evidence of AD-like
neurodegeneration and negative amyloid status, which has been
labeled suspected non-Alzheimer pathology (sNAP; Knopman
et al., 2012; Petersen et al., 2013; Prestia et al., 2013). While debate
continues regarding the underlying pathology in these individuals,
Prestia et al. (2013) also similarly reported that such individuals
with anMCI phenotype also had a high rate of conversion to clini-
cal dementia. As they note, it is worth at least considering that these
patientsmay require adaptation of themodel of biomarker change
used here, as has been recently discussed (Jack et al., 2013). It is also
worth noting that the individuals in this group in the present anal-
ysis who progressed to dementia were diagnosed clinically with
probable AD dementia rather than a non-AD dementia.
Limitations of the present study include the relatively short
follow-up period and the small number of individuals who were
amyloid-negative at baselinewith adequate longitudinal follow-up
data. Furthermore, a more broadly representative sample of indi-
viduals with MCI might be helpful to better determine whether
these ﬁndings are generalizable to clinical practice. Nevertheless,
we believe the results of the present analysis provide valuable
insights about the use of biomarkers in an MCI sample likely
to be similar to that considered for clinical trials of putative AD
interventions.
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